Massachusetts-based Berg Biosystems, LLC and GNS Healthcare, Inc. have announced a joint venture “to accelerate advancements in critical biomedical research” and reposition “existing drugs for use in new indications with collaborators.” Called MAP Biosystems LLC, the joint venture will apparently combine Berg’s Interrogative Biology™ drug discovery platform with GNS’s patented REFS™ modeling and simulation platform “to unlock the key molecular drivers of complex diseases and drug efficacy and safety.”

“MAP represents to biological investigation a new paradigm of physiological understanding based upon a robust network intelligence of disease,” Berg president and CTO Niven Narain said. “The unique combination of unbiased systems biology and artificial-intelligence based systems engineering creates a true data-driven approach to therapeutic and diagnostic development.” See Berg Biosystems/GNS Healthcare Press Release, March 2, 2011.